Gaithersburg’s Emergent BioSolutions lands large federal contract to boost development of Ebola drug

Gaithersburg’s Emergent BioSolutions Inc. (NYSE: EBS) has landed a long-term contract with the U.S. Department of Health and Human Resources to scale up manufacturing of a drug designed to treat Ebola. The drug, a monoclonal antibody known as Ebanga, was developed by Miami’s Ridgeback Biotherapeutics and approved by the Food and Drug Administration for the treatment of Ebola in December 2020.